08:20pm Wednesday 23 October 2019

Otago researchers reveal PAX gene’s role in cancer

In 2003, research led by Otago’s Professor Michael Eccles was the first in the world to show that proteins from one or more of the nine PAX genes were present in a wide variety of common cancers. Additionally, the researchers found that “silencing” the gene expression of PAX2 in ovarian and bladder cancer cells, and of PAX3 in melanoma, led to the rapid death of the cells.

Now Professor Eccles and colleagues’ investigations of PAX8, which have just been published in the leading UK journal Oncogene, reveal that silencing this gene also has a dramatic effect on cells in several kinds of tumours, but through a different mechanism.

After detecting high levels of PAX8 protein in the vast majority of kidney cancers, ovarian cancers and thyroid cancers they studied, the researchers used molecular techniques to silence PAX8 in several cancer cell lines.

“We found that these PAX8-depleted cancer cells ceased growing and dividing. The cells were essentially stopped in their tracks through the failure of multiple mechanisms and pathways crucial to their cell division cycle. They then entered into a state called senescence in which they no longer divided, and after that they ultimately died,” Professor Eccles says.

The findings suggest that PAX8 could be a good target for the development of new cancer therapies, he says.

“Any resulting drugs would be a long way down the road, but in the meantime this research helps confirm that a focus on PAX genes may prove to be a fruitful line of attack against a number of cancers,” he says.

The research was supported by grants from the Health Research Council of New Zealand. It formed the main piece of work carried out by Otago PhD graduate Caiyun (Grace) Li, who is now a postdoctoral fellow at Stanford University. Study co-authors also included Professor Antony Braithwaite and Master’s student Jen Nyman.

The research article can be accessed at: http://www.nature.com/onc/journal/vaop/ncurrent/pdf/onc2011190a.pdf

For more information, contact

Professor Michael Eccles
New Zealand Institute for Cancer Research Trust Chair in Cancer Pathology
Department of Pathology
University of Otago
Tel 64 3 479 7878
Mob 021 298 9953
Email michael.eccles@otago.ac.nz

Share on:

Health news